Montelukast Aurobindo

Montelukast, the active ingredient in Montelukast Aurobindo, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage respiratory allergic conditions.

Asthma: reduces frequency of bronchospasm and improves overall disease control. Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Allergic reactions such as rash or angioedema - Mood changes including depression or suicidal thoughts - Hepatic enzyme elevations

When prescribing Montelukast, clinicians should consider several safety measures. - Monitor liver function: consider periodic testing in patients with hepatic disease. - Assess psychiatric status: watch for mood changes, especially in adolescents. - Avoid use in patients with known hypersensitivity to montelukast. - Use caution in patients with severe renal impairment: dose adjustment may be required. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Montelukast may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Phenobarbital: induces hepatic enzymes, reducing montelukast exposure. - Rifampin: strong enzyme inducer that may lower therapeutic levels. - Ketoconazole: potent CYP3A4 inhibitor that can increase montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilatory effect may require dose adjustment. - NSAIDs: may increase risk of gastrointestinal discomfort.